Background & Aims The increasing rates of obesity and type 2 diabetes mellitus may lead to
increased prevalence of nonalcoholic fatty liver disease (NAFLD). We aimed to determine …

Background & Aims The prevalence of non-alcoholic fatty liver disease (NAFLD) is
increasing. We aimed to estimate the pooled global NAFLD incidence. Methods We …

Background Although non-alcoholic fatty liver disease (NAFLD) is commonly associated
with obesity, it is increasingly being identified in non-obese individuals. We aimed to …

Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) remain as one
of the most global problematic metabolic diseases with rapidly increasing prevalence and …

Insulin resistance (IR) plays a crucial role in the development and progression of
metabolism-related diseases such as diabetes, hypertension, tumors, and nonalcoholic fatty …

Background & Aims Nonalcoholic fatty liver disease (NAFLD) is traditionally associated with
obesity. However, there is a subtype of NAFLD, namely NAFLD in lean, that occurs without …

Under normal conditions, insulin promotes hepatic de novo lipogenesis (DNL). However,
during insulin resistance (IR), when insulin signalling is blunted and accompanied by …

Non‐alcoholic fatty liver disease (NAFLD) is one of the most common causes of hepatic
disorders. It represents a wide range of chronic liver diseases in patients with no history of …

Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in North
America and Europe, with increasing prevalence in other regions of the world. Its spectrum …

Background The efficacy and safety of insulin sensitizer in Asians with non-alcoholic
steatohepatitis (NASH) remain elusive. Aims The double-blind, randomized, placebo …